CD2-HM0P10B-100μg / 询价
CD2-HM0P10B-100μg x 5 / 询价
CD2-HM0P10B-100μg x 10 / 询价
- 客服电话
- 技术支持
FITC-equivalent Biotinylated Human CD20 Protein-VLP
Recombinant FITC-equivalent Biotinylated Human CD20 Protein-VLP is expressed from HEK293.It contains Met1-Pro297 [Accession | P11836-1].
The target protein has a predicted MW of 34.3 kDa.
Excitation Wavelength: 490 nm
Emission Wavelength: 520 nm
Less than 1EU per μg by the LAL method.
Supplied as 0.22 μm filtered solution in PBS, 150mM L-Arginine (pH 7.4).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Immobilized FITC-equivalent Biotinylated Human CD20 VLP at 5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Rituximab with the EC50 of 0.24μg/ml determined by ELISA (QC Test).
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7
(1)Ma D , Mcdevitt M R , Barendswaard E , et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66. (2)Jager U , Fridrik M , Zeitlinger M , et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
